{"_buckets": {"deposit": "4ff357d8-14ad-4df5-8206-1010a0321617"}, "_deposit": {"id": "34022", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "34022"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00034022", "sets": ["455", "562"]}, "item_6_alternative_title_1": {"attribute_name": "その他のタイトル", "attribute_value_mlt": [{"subitem_alternative_title": "9-ING-41(GSK-3阻害剤)は、腎癌に対して単剤および併用療法として有効である"}]}, "item_6_date_granted_51": {"attribute_name": "学位授与年月日", "attribute_value_mlt": [{"subitem_dategranted": "2020-03-23"}]}, "item_6_degree_grantor_49": {"attribute_name": "学位授与機関", "attribute_value_mlt": [{"subitem_degreegrantor": [{"subitem_degreegrantor_name": "新潟大学"}]}]}, "item_6_degree_name_48": {"attribute_name": "学位名", "attribute_value_mlt": [{"subitem_degreename": "博士(医学)"}]}, "item_6_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is involved in a broad range of pathological　processes including cancer. GSK-3 has two isoforms, GSK-3αand GSK-3β, and GSK-3β has been recognized as a therapeutic target for the development of new anticancer drugs. The present study aimed to investigate the antitumor effects of9-ING-41, which is a maleimide-based ATP-competitive small molecule GSK-3β inhibitor active in patients with advanced cancer. In renal cancer cell lines, treatment with 9-ING-41 alone induced cell cycle arrest and apoptosis, and autophagy inhibitors increased the antitumor effects of 9-ING-41 when used in combination. Treatment with 9-ING-41 potentiated the antitumor effects of targeted therapeutics and increased the cytotoxic effects of cytokine-activated immune cells on renal cancer cell lines. These results provided a compelling rationale for the inclusion of patients with renal cancer in studies of 9-ING-41, both as a single agent and in combination with current standard therapies.", "subitem_description_type": "Abstract"}]}, "item_6_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "International Journal of Molecular Medicine. 2020, 45(2), 315-323.", "subitem_description_type": "Other"}]}, "item_6_description_53": {"attribute_name": "学位記番号", "attribute_value_mlt": [{"subitem_description": "新大院博(医)甲第931号", "subitem_description_type": "Other"}]}, "item_6_dissertation_number_52": {"attribute_name": "学位授与番号", "attribute_value_mlt": [{"subitem_dissertationnumber": "13101甲第4697号"}]}, "item_6_full_name_3": {"attribute_name": "著者別名", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "178044", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "安楽, 力"}]}]}, "item_6_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "info:doi/10.3892/ijmm.2019.4427", "subitem_relation_type_select": "DOI"}}]}, "item_6_select_19": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "ETD"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Anraku, Tsutomu"}], "nameIdentifiers": [{"nameIdentifier": "178043", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-08-31"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "r1nmk931.pdf", "filesize": [{"value": "1.1 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1100000.0, "url": {"label": "本文", "url": "https://niigata-u.repo.nii.ac.jp/record/34022/files/r1nmk931.pdf"}, "version_id": "3771a466-ccb2-4a7b-87a2-dfbb03d77397"}, {"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-08-31"}], "displaytype": "detail", "download_preview_message": "", "file_order": 1, "filename": "r1nmk931_a.pdf", "filesize": [{"value": "571.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 571700.0, "url": {"label": "要旨", "url": "https://niigata-u.repo.nii.ac.jp/record/34022/files/r1nmk931_a.pdf"}, "version_id": "32faba86-9383-4f9d-87cc-578abae0acb4"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "glycogen synthase kinase-3", "subitem_subject_scheme": "Other"}, {"subitem_subject": "renal cell carcinoma", "subitem_subject_scheme": "Other"}, {"subitem_subject": "apoptosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "cell cycle arrest", "subitem_subject_scheme": "Other"}, {"subitem_subject": "immune cells", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "thesis", "resourceuri": "http://purl.org/coar/resource_type/c_46ec"}]}, "item_title": "Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer"}]}, "item_type_id": "6", "owner": "1", "path": ["455", "562"], "permalink_uri": "http://hdl.handle.net/10191/00051820", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-08-31"}, "publish_date": "2020-08-31", "publish_status": "0", "recid": "34022", "relation": {}, "relation_version_is_last": true, "title": ["Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer"], "weko_shared_id": null}